JPWO2019239387A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019239387A5 JPWO2019239387A5 JP2020569049A JP2020569049A JPWO2019239387A5 JP WO2019239387 A5 JPWO2019239387 A5 JP WO2019239387A5 JP 2020569049 A JP2020569049 A JP 2020569049A JP 2020569049 A JP2020569049 A JP 2020569049A JP WO2019239387 A5 JPWO2019239387 A5 JP WO2019239387A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- forms
- formula
- present application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 156
Description
［請求項１］[Claim 1]
式： formula:
［請求項２］[Claim 2]
前記化合物が、形態１１、１１ｂ、１５、１６、１７、及び１８のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of forms 11, 11b, 15, 16, 17, and 18.
［請求項３］[Claim 3]
前記化合物が、形態１１である、請求項２に記載の化合物。 The compound according to claim 2, wherein the compound is in form 11.
［請求項４］[Claim 4]
前記化合物が、形態１１及び１１ｂのうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of forms 11 and 11b.
［請求項５］[Claim 5]
前記化合物が、形態１ｓ、６、１０、５、８、及び１１のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of the forms 1s, 6, 10, 5, 8, and 11.
［請求項６］[Claim 6]
前記化合物が、形態１ｓ、６、１０、及び１１のうちの少なくとも１つである、請求項５に記載の化合物。 The compound according to claim 5, wherein the compound is at least one of the forms 1s, 6, 10, and 11.
［請求項７］[Claim 7]
前記化合物が、形態１９である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 19.
［請求項８］[Claim 8]
前記化合物が、形態１ｓ及び１６のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of the forms 1s and 16.
［請求項９］[Claim 9]
前記化合物が、形態１ｓ及び１１ｂのうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of the forms 1s and 11b.
［請求項１０］[Claim 10]
前記化合物が、形態１ｓ及び１１のうちの少なくとも１つである、請求項５に記載の化合物。 The compound according to claim 5, wherein the compound is at least one of forms 1s and 11.
［請求項１１］[Claim 11]
前記化合物が、形態１ｓ及び１７のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of forms 1s and 17.
［請求項１２］[Claim 12]
前記化合物が、形態１１ｂである、請求項９に記載の化合物。 The compound according to claim 9, wherein the compound is in form 11b.
［請求項１３］[Claim 13]
前記化合物が、形態１２である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 12.
［請求項１４］[Claim 14]
前記化合物が、形態１６である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 16.
［請求項１５］[Claim 15]
前記化合物が、形態２０である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 20.
［請求項１６］[Claim 16]
前記化合物が、形態１ｓ及び１２のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of forms 1s and 12.
［請求項１７］[Claim 17]
前記化合物が、形態１ｓ及び１５のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of forms 1s and 15.
［請求項１８］[Claim 18]
前記化合物が、形態１ｓ、１５及び１９のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of the forms 1s, 15 and 19.
［請求項１９］[Claim 19]
前記化合物が、形態１ｓ及び１８のうちの少なくとも１つである、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is at least one of forms 1s and 18.
［請求項２０］[Claim 20]
前記化合物が、形態１５である、請求項１７に記載の化合物。 The compound according to claim 17, wherein the compound is in form 15.
［請求項２１］[Claim 21]
前記化合物が、形態１７である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 17.
［請求項２２］[Claim 22]
前記化合物が、形態１８である、請求項１９に記載の化合物。 The compound according to claim 19, wherein the compound is in form 18.
［請求項２３］[Claim 23]
前記化合物が、形態２１である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 21.
［請求項２４］[Claim 24]
前記化合物が、形態２２である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 22.
［請求項２５］[Claim 25]
前記化合物が、形態２３である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 23.
［請求項２６］[Claim 26]
前記化合物が、形態２４である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 24.
［請求項２７］[Claim 27]
前記化合物が、形態２５である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 25.
［請求項２８］[Claim 28]
前記化合物が、形態２６である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 26.
［請求項２９］[Claim 29]
前記化合物が、形態２７である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 27.
［請求項３０］[Claim 30]
前記化合物が、形態２８である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 28.
［請求項３１］[Claim 31]
前記化合物が、形態２９である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 29.
［請求項３２］[Claim 32]
前記化合物が、形態３０である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 30.
［請求項３３］[Claim 33]
前記化合物が、形態３１である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 31.
［請求項３４］[Claim 34]
前記化合物が、形態３２である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 32.
［請求項３５］[Claim 35]
前記化合物が、形態３３である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 33.
［請求項３６］[Claim 36]
前記化合物が、形態３４である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 34.
［請求項３７］[Claim 37]
前記化合物が、形態３５である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 35.
［請求項３８］[Claim 38]
前記化合物が、形態３６である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 36.
［請求項３９］[Claim 39]
前記化合物が、形態３７である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 37.
［請求項４０］[Claim 40]
前記化合物が、形態３８である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 38.
［請求項４１］[Claim 41]
前記化合物が、形態３９である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 39.
［請求項４２］[Claim 42]
前記化合物が、形態４０である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 40.
［請求項４３］[Claim 43]
前記化合物が、形態４１である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 41.
［請求項４４］[Claim 44]
前記化合物が、形態４２である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 42.
［請求項４５］[Claim 45]
前記化合物が、形態４３である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 43.
［請求項４６］[Claim 46]
前記化合物が、形態４４である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 44.
［請求項４７］[Claim 47]
前記化合物が、形態４５である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 45.
［請求項４８］[Claim 48]
前記化合物が、形態４６である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 46.
［請求項４９］[Claim 49]
前記化合物が、形態４７である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 47.
［請求項５０］[Claim 50]
前記化合物が、形態４８である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 48.
［請求項５１］[Claim 51]
前記化合物が、形態４９である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 49.
［請求項５２］[Claim 52]
前記化合物が、形態５０である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 50.
［請求項５３］[Claim 53]
前記化合物が、形態５１である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 51.
［請求項５４］[Claim 54]
前記化合物が、形態５２である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 52.
［請求項５５］[Claim 55]
前記化合物が、形態５３である、請求項１に記載の化合物。 The compound according to claim 1, wherein the compound is in form 53.
Claims (24)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685737P | 2018-06-15 | 2018-06-15 | |
| US62/685,737 | 2018-06-15 | ||
| US201962846290P | 2019-05-10 | 2019-05-10 | |
| US62/846,290 | 2019-05-10 | ||
| PCT/IB2019/055005 WO2019239387A1 (en) | 2018-06-15 | 2019-06-14 | Small molecule inhibitors of the jak family of kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021528391A JP2021528391A (en) | 2021-10-21 |
| JPWO2019239387A5 true JPWO2019239387A5 (en) | 2022-04-11 |
Family
ID=67766195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569049A Pending JP2021528391A (en) | 2018-06-15 | 2019-06-14 | Small molecule inhibitors of JAK family kinases |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20200017498A1 (en) |
| EP (1) | EP3807277A1 (en) |
| JP (1) | JP2021528391A (en) |
| KR (1) | KR20210021342A (en) |
| CN (1) | CN112313233A (en) |
| AU (1) | AU2019286641A1 (en) |
| BR (1) | BR112020024744A2 (en) |
| CA (1) | CA3101438A1 (en) |
| CL (1) | CL2020003227A1 (en) |
| CO (1) | CO2020015396A2 (en) |
| CR (1) | CR20200603A (en) |
| EC (1) | ECSP20080817A (en) |
| IL (1) | IL279314A (en) |
| JO (1) | JOP20200311A1 (en) |
| MA (1) | MA52900A (en) |
| MX (1) | MX2020013688A (en) |
| NI (1) | NI202000100A (en) |
| PE (1) | PE20212113A1 (en) |
| PH (1) | PH12020551984A1 (en) |
| SG (1) | SG11202011691PA (en) |
| TW (1) | TW202016110A (en) |
| UY (1) | UY38262A (en) |
| WO (1) | WO2019239387A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| HUE059274T2 (en) | 2016-12-16 | 2022-11-28 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
| US20220288041A1 (en) * | 2021-03-11 | 2022-09-15 | Janssen Pharmaceutica Nv | Small molecule inhibitor of the jak family of kinases |
| CN113292561A (en) * | 2021-05-22 | 2021-08-24 | 中国药科大学 | Compound with dipyrrolopyridine structure, preparation method and medical application |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| EP1173435B1 (en) | 1999-04-23 | 2003-07-30 | SmithKline Beecham plc | Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| AR033485A1 (en) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME |
| WO2003101991A1 (en) | 2002-05-31 | 2003-12-11 | Schering Corporation | Xanthine phosphodiesterase v inhibitor polymorphs |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| EP1902029B2 (en) | 2005-07-01 | 2022-02-16 | Wyeth LLC | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
| TW201612182A (en) | 2008-06-10 | 2016-04-01 | Abbvie Inc | Novel tricyclic compounds |
| EP2473510B1 (en) | 2009-09-03 | 2014-07-23 | Bristol-Myers Squibb Company | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer |
| CN102711470A (en) | 2009-12-01 | 2012-10-03 | 雅培制药有限公司 | Novel tricyclic compounds |
| ES2637588T3 (en) | 2009-12-01 | 2017-10-13 | Abbvie Inc. | New tricyclic compounds |
| CA2781578A1 (en) | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| EP2534258B1 (en) | 2010-02-10 | 2017-09-20 | Genon Biotechnologies OY | Dual activity kinase domains and uses thereof |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| US9475813B2 (en) | 2013-02-08 | 2016-10-25 | Nissan Chemical Industries, Ltd. | Tricyclic pyrrolopyridine compound, and JAK inhibitor |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| NZ725001A (en) | 2014-05-14 | 2021-08-27 | Nissan Chemical Ind Ltd | Tricyclic compound and jak inhibitor |
| MX2020011774A (en) | 2015-05-28 | 2021-06-01 | Theravance Biopharma R&D Ip Llc | Naphthyridine compounds as jak kinase inhibitors. |
| EP3371332A4 (en) | 2015-11-04 | 2019-04-03 | Mayo Foundation for Medical Education and Research | Methods and materials for treating autoimmune conditions |
| JOP20190053A1 (en) | 2016-09-23 | 2019-03-21 | Novartis Ag | Aza-indazole compounds for use in tendon and/or ligament injuries |
| SI3640251T1 (en) | 2016-10-24 | 2022-04-29 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinoline derivatives useful in the treatment of cancer |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| KR20190092539A (en) | 2016-12-16 | 2019-08-07 | 바스프 에스이 | Insecticide compound |
| JP6637641B1 (en) | 2016-12-16 | 2020-01-29 | ファイザー・インク | GLP-1 receptor agonists and uses thereof |
| HUE059274T2 (en) | 2016-12-16 | 2022-11-28 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases |
| MX2019006047A (en) | 2016-12-16 | 2019-10-02 | Nestle Sa | Oligosaccharides for flavour generation. |
| CR20190252A (en) | 2016-12-16 | 2019-08-26 | Lilly Co Eli | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
| EP3568396B1 (en) | 2017-01-11 | 2020-11-11 | Leo Pharma A/S | Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
| JOP20190183B1 (en) | 2017-01-30 | 2022-09-15 | Astrazeneca Ab | Estrogen receptor modulators |
| BR112019021992A2 (en) | 2017-04-21 | 2020-06-09 | Kyn Therapeutics | indole ahr inhibitors and uses thereof |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
| US20200338051A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
-
2019
- 2019-06-13 TW TW108120432A patent/TW202016110A/en unknown
- 2019-06-14 WO PCT/IB2019/055005 patent/WO2019239387A1/en active Application Filing
- 2019-06-14 PE PE2020001995A patent/PE20212113A1/en unknown
- 2019-06-14 MX MX2020013688A patent/MX2020013688A/en unknown
- 2019-06-14 JP JP2020569049A patent/JP2021528391A/en active Pending
- 2019-06-14 MA MA052900A patent/MA52900A/en unknown
- 2019-06-14 JO JOP/2020/0311A patent/JOP20200311A1/en unknown
- 2019-06-14 CN CN201980040198.7A patent/CN112313233A/en active Pending
- 2019-06-14 UY UY0001038262A patent/UY38262A/en unknown
- 2019-06-14 SG SG11202011691PA patent/SG11202011691PA/en unknown
- 2019-06-14 BR BR112020024744-8A patent/BR112020024744A2/en not_active Application Discontinuation
- 2019-06-14 CA CA3101438A patent/CA3101438A1/en active Pending
- 2019-06-14 KR KR1020217000012A patent/KR20210021342A/en not_active Application Discontinuation
- 2019-06-14 EP EP19759032.6A patent/EP3807277A1/en active Pending
- 2019-06-14 CR CR20200603A patent/CR20200603A/en unknown
- 2019-06-14 AU AU2019286641A patent/AU2019286641A1/en active Pending
- 2019-09-24 US US16/581,081 patent/US20200017498A1/en not_active Abandoned
-
2020
- 2020-01-29 US US16/776,243 patent/US11066406B2/en active Active
- 2020-11-19 PH PH12020551984A patent/PH12020551984A1/en unknown
- 2020-12-09 CO CONC2020/0015396A patent/CO2020015396A2/en unknown
- 2020-12-09 IL IL279314A patent/IL279314A/en unknown
- 2020-12-11 NI NI202000100A patent/NI202000100A/en unknown
- 2020-12-11 CL CL2020003227A patent/CL2020003227A1/en unknown
- 2020-12-14 EC ECSENADI202080817A patent/ECSP20080817A/en unknown
-
2021
- 2021-07-15 US US17/377,249 patent/US11787807B2/en active Active